FDA Warns Korean Firm Soleo For GMP Violations, Unapproved Shampoo Drug
Executive Summary
Soleo’s Marum GENtLE THERAPY Shampoo, marketed as an anti-dandruff and hair-growth treatment, is an unapproved new drug, according to FDA. The agency’s warning letter, citing “significant” CGMP violations, follows an August 2018 inspection of the firm’s Pyeongtaek-based facility.
You may also be interested in...
Wild Child Netted Down Under In US FDA Initiative To Inspect All Drug Facilities
FDA says Wild Child, which provides products as a contract manufacturer and for private label sales, violated drug GMPs for products including sun care, lice treatment and acne lotion and attempted to avoid US testing standards by relying on Australian mandates.
Scientific Solutions Global's Formulations Miss OTC Monographs Mark – FDA
Firms' BioTemper, bare and Urea brand products, as formulated and labeled, are unapproved drugs that need approval through NDAs before being sold in US, FDA says in warning. Separate websites firm operates for each brand continues offering sales.
P&G’s NIOXIN Shows How To Address Hair Loss Without An FDA Warning
With FDA scrutinizing the marketplace for cosmetics promoted as drugs, and a clear cautionary statement from the agency about topical products marketed as hair growers or hair-loss preventers, beauty firms have little choice but to incorporate approved OTC drug ingredients in such products. P&G’s professional hair-care brand NIOXIN has done just that with its new Advanced Thinning range featuring minoxidil.